Business Context and Reporting Period
This Form 8-K was filed by Pulse Biosciences, Inc. on July 27, 2018. The report addresses a governance change involving the Board of Directors and the resulting impact on the company's compliance with Nasdaq listing standards.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and regulatory compliance matters.
Material Changes
- Committee Membership Change: Maky Zanganeh, D.D.S., requested and was granted release from her roles on the Audit and Compensation Committees due to personal reasons, though she remains a director.
- Audit Committee Composition: The release reduced the Audit Committee membership from three to two members.
- Regulatory Non-Compliance: The reduction in members caused the company to fall out of compliance with Nasdaq Listing Rule 5605, which requires a minimum of three independent directors on the Audit Committee.
Outlook, Risks, and Management Commentary
- Nasdaq Notification: The company notified Nasdaq on July 27, 2018, and received a formal letter on July 30, 2018, confirming non-compliance.
- Cure Period: The company has been granted a cure period until the earlier of the next annual meeting of stockholders or July 27, 2019, to regain compliance.
- Management Plan: Management expressed full confidence in regaining compliance before the deadline by appointing an additional independent director to the Audit Committee.
Investor Verification Checklist
- Verify the appointment of a new independent director to the Audit Committee to ensure compliance is restored before the July 27, 2019 deadline.
- Monitor future filings for confirmation of the new committee member's qualifications and independence status.
- Check for any subsequent correspondence from Nasdaq regarding the status of the cure period.